ROY GUHAROY, Pharm.D., M.B.A., FASHP, FCCP, FCP (Rguharoy1@Umassmed.edu) is a clinical professor of medicine at the University of Massachusetts Medical School. He earned his Pharm.D. from the University of Minnesota and M.B.A. from Peter Drucker Graduate School of Management. He has practiced in both academic and community-based settings, spanning from clinical pharmacist to serving as chief pharmacy executive at SUNY-Upstate, University of Massachusetts, Ascension, and Baptist Health System. A strong advocate of advanced pharmacy practice and innovative patient centered care model from early in his career, Roy has championed enterprise-level innovative services implementing team-based care, medication safety initiatives, supply chain management, medication access for the poor and vulnerable, research, scholarship, educating future generation of medical-nursing-pharmacy professionals, and expansion of student training and residency programs. He has published 75 peer-reviewed articles and has given 260 invited presentations. He was the recipient of the ISMP Cheers Award in 2008 and 2016.
Roy’s service to ASHP has spanned his entire career, including serving on the Council on Public Policy, Pharmacy Practice, SPPL SAG on Patient Care Quality, SSPP SAG on Outcomes Value, and as a delegate of New York and Massachusetts Society of Health-System Pharmacists for 7 years. He served as the president of the Central New York Society of Health-System Pharmacists, board member of the Massachusetts Health-System Pharmacists (MSHP) for 4 years and numerous committees of the New York Council of Health-System Pharmacists (NYSCHP). He was the recipient of 2000 NYSCHP Pharmacist of the Year and 2012 MSHP Practitioner Excellence Award.
Meet Roy Guharoy
The COVID-19 pandemic proved the vital role of the pharmacists during the public health crisis of the century. My colleagues across the nation have worked tirelessly to develop evidence-based therapy protocols, clinical monitoring, mitigate drug shortages, and lead community mass vaccination programs. The U.S. healthcare model is undergoing profound transformations and drastic changes will occur in the post-COVID era. Pharmacists are uniquely positioned to lead the future care delivery model based on the quality, outcomes, and value delivered by healthcare teams. As a profession, we need to be ahead of the curve and not settle for the status quo. However, technological and resource gaps stand as barriers. Moving forward, ASHP needs to work with other stakeholders to augment efforts to close the gaps:
- Pharmacist provider status allowing patients access to pharmaceutical care
- Optimize telehealth to connect pharmacists with patients and other team members in clinics reimbursable by third-party payers
- Restore funding for PGY2 programs to expand number of specialty-trained pharmacists
- Develop standardized training and career advancement programs for technicians
- Lead efforts to build a pharmacy community based on diversity and inclusion
- Identify evidence on best patient-specific therapy through advances in healthcare technologies and interoperability via high quality data aggregation and big data analytics
- Promote comparative effectiveness trials for drug approvals
- Develop a national metric to ensure rapid adoption of evidence-based practices by healthcare organizations.
I will be honored to represent you on the ASHP Board of Directors.